Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Investing.com - Jefferies downgraded Opko Health (NASDAQ:OPK) from Buy to Hold on Thursday, while lowering its price target to $1.60 from $2.00.
The downgrade comes as Jefferies expressed concerns about flat year-over-year guidance of $32-35 million for Ngenla, Opko’s growth hormone product developed with Pfizer, for 2026.
Jefferies noted that Ngenla sales have remained flat for seven consecutive quarters since its launch, prompting the firm to reduce its estimates for the product’s future performance.
While acknowledging potential in Opko’s drug pipeline, Jefferies characterized these programs as still early-stage with unclear catalysts, making growth challenging under the current business structure.
The firm maintained that Opko remains interesting from a sum-of-parts valuation perspective, with potential upside if the company sells the remainder of its diagnostics business.
In other recent news, Opko Health Inc. reported its financial results for the third quarter of 2025, showcasing a stronger-than-expected performance. The company achieved a net income of $21.6 million, or $0.03 per share, surpassing analysts’ expectations of a loss of $0.06 per share. However, the company’s revenue was $151.6 million, which fell short of the anticipated $160.78 million. These results indicate a mixed performance, with earnings exceeding projections but revenue slightly underperforming. There were no significant mergers or acquisitions announced in conjunction with these earnings. Additionally, there has been no recent analyst upgrade or downgrade reported for Opko Health. These developments provide investors with a clearer view of the company’s current financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.